HRP20231729T1 - Kombinirana terapija za kopb - Google Patents
Kombinirana terapija za kopb Download PDFInfo
- Publication number
- HRP20231729T1 HRP20231729T1 HRP20231729TT HRP20231729T HRP20231729T1 HR P20231729 T1 HRP20231729 T1 HR P20231729T1 HR P20231729T T HRP20231729T T HR P20231729TT HR P20231729 T HRP20231729 T HR P20231729T HR P20231729 T1 HRP20231729 T1 HR P20231729T1
- Authority
- HR
- Croatia
- Prior art keywords
- inhalation
- therapy
- pharmaceutical
- use according
- formoterol
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 9
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 8
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 8
- 235000017274 Diospyros sandwicensis Nutrition 0.000 claims 7
- 101000972489 Homo sapiens Laminin subunit alpha-1 Proteins 0.000 claims 7
- 241000282838 Lama Species 0.000 claims 7
- 102100022746 Laminin subunit alpha-1 Human genes 0.000 claims 7
- 230000004913 activation Effects 0.000 claims 7
- 238000001994 activation Methods 0.000 claims 7
- 238000002664 inhalation therapy Methods 0.000 claims 7
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 claims 6
- 239000000443 aerosol Substances 0.000 claims 6
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims 5
- 230000000052 comparative effect Effects 0.000 claims 5
- 230000005713 exacerbation Effects 0.000 claims 5
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 5
- 229960002848 formoterol Drugs 0.000 claims 5
- 229960000193 formoterol fumarate Drugs 0.000 claims 5
- 229940125389 long-acting beta agonist Drugs 0.000 claims 5
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 150000005828 hydrofluoroalkanes Chemical class 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 3
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims 3
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 3
- 229960004436 budesonide Drugs 0.000 claims 3
- 229960002462 glycopyrronium bromide Drugs 0.000 claims 3
- 239000008249 pharmaceutical aerosol Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229960004017 salmeterol Drugs 0.000 claims 3
- 229940110309 tiotropium Drugs 0.000 claims 3
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 3
- 229960000257 tiotropium bromide Drugs 0.000 claims 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 229940000425 combination drug Drugs 0.000 claims 2
- 239000006184 cosolvent Substances 0.000 claims 2
- 150000007522 mineralic acids Chemical class 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000003380 propellant Substances 0.000 claims 2
- DQHNAVOVODVIMG-RGECMCKFSA-M spiriva Chemical compound [Br-].C([C@@H]1[N+]([C@H](C2)[C@@H]3[C@H]1O3)(C)C)C2OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-RGECMCKFSA-M 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 1
- -1 FF dihydrate Chemical class 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 229960003728 ciclesonide Drugs 0.000 claims 1
- 150000004683 dihydrates Chemical class 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims 1
- 229960004078 indacaterol Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (9)
1. Farmaceutski sastav aerosola za inhalaciju, koji sadrži fiksnu kombinaciju:
(a) glikopironijevog bromida;
(b) formoterola ili njegove solvatne soli; i
(c) beklometazon diproprionata,
sve potpuno otopljeno u hidrofluoralkanskom (HFA) potisnom plinu i kootapalu, pri čemu sastav također sadrži anorgansku kiselinu kao sredstvo za stabilizaciju;
za upotrebu u smanjenju umjerene/teške stope pogoršanja KOPB-a u podskupini pacijenata s KOPB-om s više od jednog pogoršanja u prethodnoj godini terapije;
pri čemu je stopa pogoršanja umjerene/teške KOPB-a u pacijenata smanjena za više od 20% u usporedbi s komparativnom inhalacijskom terapijom koja se sastoji od ex tempore otvorene trostruke kombinacije pojedinačne LAMA i kombinacije fiksne doze LABA+ICS.
2. Farmaceutski sastav aerosola za inhalaciju za upotrebu prema patentnom zahtjevu 1, pri čemu je u komparativnoj inhalacijiskoj terapiji pojedinačna LAMA tiotropijev bromid.
3. Farmaceutski sastav aerosola za inhalaciju za upotrebu prema patentnom zahtjevu 1 ili 2, pri čemu je u komparativnoj inhalacijiskoj terapiji LABA formoterol fumarat, a ICS je beklometazon dipropionat.
4. Farmaceutski sastav aerosola za inhalaciju za upotrebu prema patentnom zahtjevu 2 ili 3, pri čemu je u komparativnoj inhalacijiskoj terapiji (i) pojedinačna LAMA tiotropijev bromid suhi prašak za inhalaciju (Spiriva Handihaler DPI) i (ii) LABA+ICS je formoterol fumarat + beklometazon dipropionat otopljen u hidrofluoralkanu (HFA) potisnom plinu i ko-otapalu, koji nadalje sadrži anorgansku kiselinu kao stabilizirajuće sredstvo (Foster pMDI).
5. Farmaceutski sastav aerosola za inhalaciju za upotrebu prema patentnom zahtjevu 4, pri čemu se inhalirani farmaceutski sastav sastoji od fiksne kombinacije beklometazon dipropionata (BDP) 100 µg po aktivaciji, formoterol fumarat (FF) dihidrata 6 µg po aktivaciji i glikopironijevog bromida (GB) 12,5 µg po aktivaciji potpuno otopljenih u HFA 134a 87,82% masenog udjela, bezvodnom etanolu 12% masenog udjela i 1M HCl 13,44 µg po aktivaciji, primijenjenih u dvije aktivacije bis in die (b.i.d.), i pri čemu se komparativna inhalacijska terapija sastoji od ex tempore otvorene trostruke kombinacije tiotropijevog bromida suhog praška za inhalaciju 18 µg po aktivaciji jednom dnevno (Spiriva Handihaler DPI) i kombinacije fiksne doze FF dihidrata 6 µg po aktivaciji + BDP otopljenog u HFA 134a, bezvodnog etanola i stabilizirajuće količine 1M HCl (Foster 100/6 pMDI) primijenjene u dvije aktivacije bis in die.
6. Farmaceutski sastav aerosola za inhalaciju za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu je podskupina pacijenata s više od jednog pogoršanja u prethodnoj godini terapije primala do dva mjeseca prije pregleda, dvostruku inhalacijsku terapiju ICS + LABA ili ICS + LAMA ili LABA + LAMA ili pojedinačnu inhalacijsku terapiju s LAMA-om.
7. Farmaceutski sastav aerosola za inhalaciju za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 6, pri čemu je podskupina pacijenata s više od jednog pogoršanja u prethodnoj godini terapije, primala do dva mjeseca prije pregleda dvostruku inhalacijsku terapiju koja se sastoji od:
- fiksne kombinacije BDP+FORMOTEROL; BUDESONID+FORMOTEROL ili FLUTIKAZON+SALMETEROL ili
- slobodne (otvorene) kombinacije BDP-a, BUDESONIDA, CIKLESONIDA ili FLUTIKAZONA plus FORMOTEROL, INDAKATEROL ili SALMETEROL
ili od
BDP-a, BUDESONIDA, CIKLESONIDA ili FLUTIKAZONA plus GLIKOPIRONIJEVOG BROMIDA ili TIOTROPIJA
ili od
FORMOTEROLA, INDAKATEROLA ili SALMETEROLA plus GLIKOPIRONIJEVOG BROMIDA ili TIOTROPIJA ili
- pojedinačne LAMA odabrane između GLIKOPIRONIJEVOG BROMIDA ili TIOTROPIJA.
8. Farmaceutski sastav aerosola za inhalaciju za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu je stopa pogoršanja umjerene/teške KOPB kod pacijenata smanjena za oko 29%.
9. Farmaceutski sastav aerosola za inhalaciju za upotrebu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je sastav sposoban osigurati, nakon aktivacije, udio veći ili jednak 30% emitiranih čestica promjera jednakog do ili manje od 1,1 mikrona kako je definirano stupnjevima sadržaja S6-AF Andersenovog kaskadnog impaktora, u odnosu na ukupnu dozu sitnih čestica sakupljenih u stupnjevima S3-AF udarne glave.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16184608 | 2016-08-17 | ||
| PCT/EP2017/070850 WO2018033598A1 (en) | 2016-08-17 | 2017-08-17 | Combination therapy for copd |
| EP17758473.7A EP3500241B1 (en) | 2016-08-17 | 2017-08-17 | Combination therapy for copd |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231729T1 true HRP20231729T1 (hr) | 2024-03-15 |
Family
ID=56740118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231729TT HRP20231729T1 (hr) | 2016-08-17 | 2017-08-17 | Kombinirana terapija za kopb |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10098837B2 (hr) |
| EP (1) | EP3500241B1 (hr) |
| JP (1) | JP7384666B2 (hr) |
| KR (1) | KR102440850B1 (hr) |
| CN (1) | CN109562061A (hr) |
| AU (1) | AU2017314153B2 (hr) |
| BR (1) | BR112019003173A2 (hr) |
| CA (1) | CA3029481A1 (hr) |
| DK (1) | DK3500241T3 (hr) |
| EA (1) | EA201990514A1 (hr) |
| ES (1) | ES2961242T3 (hr) |
| FI (1) | FI3500241T3 (hr) |
| GE (1) | GEP20227418B (hr) |
| HR (1) | HRP20231729T1 (hr) |
| HU (1) | HUE064623T2 (hr) |
| IL (1) | IL264612B2 (hr) |
| LT (1) | LT3500241T (hr) |
| MA (1) | MA45984B1 (hr) |
| MD (1) | MD3500241T2 (hr) |
| MX (1) | MX2019001587A (hr) |
| NZ (1) | NZ750214A (hr) |
| PH (1) | PH12019500315A1 (hr) |
| PL (1) | PL3500241T3 (hr) |
| PT (1) | PT3500241T (hr) |
| RS (1) | RS64751B1 (hr) |
| SG (1) | SG11201900471VA (hr) |
| SI (1) | SI3500241T1 (hr) |
| UA (1) | UA123231C2 (hr) |
| WO (1) | WO2018033598A1 (hr) |
| ZA (1) | ZA201900239B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| CN102665679B (zh) | 2009-12-23 | 2014-11-26 | 奇斯药制品公司 | 用于copd的联合治疗 |
| CN112438966B (zh) * | 2019-08-30 | 2022-08-26 | 四川普锐特药业有限公司 | 一种医用定量吸入气雾剂 |
| MX2022004781A (es) | 2019-12-02 | 2022-05-16 | Chiesi Farm Spa | Lata de acero inoxidable para inhaladores dosificadores presurizados. |
| AU2021213883A1 (en) * | 2020-01-28 | 2022-07-21 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| CN115087431A (zh) * | 2020-02-20 | 2022-09-20 | 奇斯药制品公司 | 包含缓冲药物制剂的加压定量吸入器 |
| CN115989032A (zh) | 2020-07-31 | 2023-04-18 | 化学研究有限公司 | 用于吸入施用的组合疗法 |
| MX2023003754A (es) * | 2020-10-09 | 2023-04-24 | Chiesi Farm Spa | Formulacion farmaceutica para inhalador presurizado de dosis medidas. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| AU2000250701B2 (en) | 2000-05-22 | 2004-07-01 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
| EP1321159A1 (en) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices |
| JP4819699B2 (ja) | 2004-02-06 | 2011-11-24 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | 喘息及びｃｏｐｄの長期間の治療のための抗コリン作用薬及びグルココルチコイドの組合せ剤 |
| GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| CA2603433A1 (en) | 2005-03-30 | 2006-10-05 | Schering Corporation | Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| CN102665679B (zh) * | 2009-12-23 | 2014-11-26 | 奇斯药制品公司 | 用于copd的联合治疗 |
| SG11201501434PA (en) | 2012-08-29 | 2015-03-30 | Chiesi Farma Spa | Aerosol inhalation device |
| EP2999460A1 (en) | 2013-05-22 | 2016-03-30 | Pearl Therapeutics, Inc. | Compositions, methods&systems for respiratory delivery of three or more active agents |
| MY182861A (en) | 2013-12-30 | 2021-02-05 | Chiesi Farm Spa | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination |
| BR112016014586A2 (pt) | 2013-12-30 | 2017-08-08 | Chiesi Farm Spa | Composição de solução de aerossol pressurizado estável da combinação de brometo de glicopirrônio e formoterol |
-
2017
- 2017-07-28 US US15/663,364 patent/US10098837B2/en active Active
- 2017-08-17 PL PL17758473.7T patent/PL3500241T3/pl unknown
- 2017-08-17 NZ NZ750214A patent/NZ750214A/en unknown
- 2017-08-17 CN CN201780049986.3A patent/CN109562061A/zh active Pending
- 2017-08-17 UA UAA201902491A patent/UA123231C2/uk unknown
- 2017-08-17 ES ES17758473T patent/ES2961242T3/es active Active
- 2017-08-17 LT LTEPPCT/EP2017/070850T patent/LT3500241T/lt unknown
- 2017-08-17 BR BR112019003173A patent/BR112019003173A2/pt unknown
- 2017-08-17 SI SI201731458T patent/SI3500241T1/sl unknown
- 2017-08-17 CA CA3029481A patent/CA3029481A1/en active Pending
- 2017-08-17 WO PCT/EP2017/070850 patent/WO2018033598A1/en active Application Filing
- 2017-08-17 MX MX2019001587A patent/MX2019001587A/es unknown
- 2017-08-17 HR HRP20231729TT patent/HRP20231729T1/hr unknown
- 2017-08-17 FI FIEP17758473.7T patent/FI3500241T3/fi active
- 2017-08-17 MA MA45984A patent/MA45984B1/fr unknown
- 2017-08-17 MD MDE20190710T patent/MD3500241T2/ro unknown
- 2017-08-17 GE GEAP201715023A patent/GEP20227418B/en unknown
- 2017-08-17 JP JP2019530539A patent/JP7384666B2/ja active Active
- 2017-08-17 DK DK17758473.7T patent/DK3500241T3/da active
- 2017-08-17 HU HUE17758473A patent/HUE064623T2/hu unknown
- 2017-08-17 RS RS20231015A patent/RS64751B1/sr unknown
- 2017-08-17 EP EP17758473.7A patent/EP3500241B1/en active Active
- 2017-08-17 EA EA201990514A patent/EA201990514A1/ru unknown
- 2017-08-17 SG SG11201900471VA patent/SG11201900471VA/en unknown
- 2017-08-17 AU AU2017314153A patent/AU2017314153B2/en active Active
- 2017-08-17 PT PT177584737T patent/PT3500241T/pt unknown
- 2017-08-17 KR KR1020197004574A patent/KR102440850B1/ko active IP Right Grant
-
2019
- 2019-01-14 ZA ZA2019/00239A patent/ZA201900239B/en unknown
- 2019-02-03 IL IL264612A patent/IL264612B2/en unknown
- 2019-02-14 PH PH12019500315A patent/PH12019500315A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231729T1 (hr) | Kombinirana terapija za kopb | |
| JP2019528316A5 (hr) | ||
| JP2010132695A5 (hr) | ||
| HRP20180944T1 (hr) | Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola | |
| PE20160853A1 (es) | Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) | |
| NZ600789A (en) | Aerosol formulation for copd | |
| PE20160155A1 (es) | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos | |
| AR098982A1 (es) | Composición combinada de bromuro de glicopirronio y formoterol en solución estable presurizada para aerosol | |
| ECSP088653A (es) | Formulacion farmacéutica para aerosoles con dos o más principios activos y al menos una sustancia tensoactiva | |
| RS52940B (en) | PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS | |
| PE20091672A1 (es) | Nueva dosificacion y formulacion | |
| AR081540A1 (es) | Proceso para proveer particulas con cargas electroestaticas reducidas | |
| JP2013542940A5 (hr) | ||
| RU2013142268A (ru) | Фармацевтическая композиция | |
| BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
| NZ627837A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| MX2023003754A (es) | Formulacion farmaceutica para inhalador presurizado de dosis medidas. | |
| AR123674A2 (es) | Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona | |
| AR091161A1 (es) | Composicion farmaceutica para inhalacion, metodo, uso | |
| UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
| NZ591174A (en) | Metered dose inhaler | |
| CO6270213A2 (es) | Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion | |
| MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
| PE20221867A1 (es) | Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada | |
| WO2020036478A3 (es) | Composición farmacéutica sinérgica de aceclofenaco y betametasona para el tratamiento del dolor en las formas localizadas de afecciones reumáticas |